Article Figures & Data
Figures
- Fig 1.
The ROIs of the 2 slabs in bilateral hemispheres. ROI maps show the level of the basal ganglia (A), including ACA territory (1–2), MCA territory (3–6), PCA territory (7–8), basal ganglia (9–10), anterior CWS (11–12), and posterior CWS (13–14); and also show the level of the body lateral cerebral ventricle (B), including ACA territory (15–16), MCA territory (17–22), PCA territory (23–24), anterior CWS (25–26), posterior CWS (27–28), and IWS (29–34).
- Fig 2.
95% stenosis (A) of right carotid artery in a patient aged 71 years and basically normal (B) after CAS.
- Fig 3.
On the level of the basal ganglia (left) and the body lateral cerebral ventricle (right), CBF is decreased before CAS in the right hemisphere (A, B); CBF in the affected hemisphere is improved significantly at 1 week after CAS (C, D); at 1 year after CAS, CBF is similar to that shown at 1 week after CAS (E, F).
- Fig 4.
On the level of the basal ganglia (left) and the body lateral cerebral ventricle (right), MTT is increased before CAS in the right hemisphere compared with the left hemisphere (A, B). This hemispheric difference disappeared at 1 week after CAS (C, D); compared with 1 week after CAS, no hemodynamic changes were found at 1 year after CAS (E, F).
- Fig 5.
On the level of the basal ganglia (left) and the body lateral cerebral ventricle (right), CBV is decreased before CAS in the right hemisphere (A, B); this hemispheric difference has not disappeared at 1 week after CAS (C, D) or at 1 year after CAS (E, F).
Tables
- Table 1:
Comparison of relative perfusion parameters among pretreatment, 1 week, and 1 year groups
rCBF rCBV rMTT Pre 1 week 1 year P Pre 1 week 1 year P Pre 1 week 1 year P ACA territory 0.86 ± 0.06 0.95 ± 0.04 0.97 ± 0.07 0.00 1.02 ± 0.03 1.00 ± 0.01 0.99 ± 0.04 0.12 1.17 ± 0.05 1.03 ± 0.04 1.01 ± 0.06 0.00 MCA territory 0.81 ± 0.04 1.06 ± 0.05 1.03 ± 0.07 0.00 1.13 ± 0.09 1.12 ± 0.07 1.07 ± 0.08 0.06 1.41 ± 0.06 1.08 ± 0.04 1.07 ± 0.04 0.00 PCA territory 0.96 ± 0.06 1.00 ± 0.04 0.99 ± 0.02 0.08 1.02 ± 0.06 1.02 ± 0.04 1.03 ± 0.05 0.57 1.07 ± 0.05 1.05 ± 0.05 1.03 ± 0.06 0.06 Basal ganglia 0.85 ± 0.06 0.97 ± 0.04 0.96 ± 0.04 0.00 1.02 ± 0.07 0.98 ± 0.02 1.01 ± 0.05 0.16 1.20 ± 0.06 1.06 ± 0.04 1.05 ± 0.04 0.00 Anterior CWS 0.78 ± 0.03 0.97 ± 0.03 0.96 ± 0.02 0.00 1.08 ± 0.05 1.06 ± 0.06 1.05 ± 0.07 0.24 1.41 ± 0.05 1.10 ± 0.05 1.09 ± 0.04 0.00 Posterior CWS 0.77 ± 0.03 1.00 ± 0.02 0.98 ± 0.03 0.00 1.10 ± 0.07 1.09 ± 0.09 1.04 ± 0.06 0.11 1.43 ± 0.10 1.07 ± 0.06 1.08 ± 0.06 0.00 IWS 0.80 ± 0.04 0.94 ± 0.03 0.93 ± 0.04 0.00 1.05 ± 0.06 1.02 ± 0.05 1.04 ± 0.05 0.19 1.29 ± 0.10 1.09 ± 0.05 1.11 ± 0.07 0.00 -
Note:—For rCBF and rMTT, except in PCA territory, pretreatment vs 1 week or 1 year after CAS, P < 0.01; 1 week vs 1 year, P > 0.05.
-
Pre 1 week 1 year P MRS Score 2.10 ± 0.64 2.05 ± 0.61 0.91 ± 0.30 0.00 -
Note:—For MRS, 1 week after CAS vs pretreatment, P > 0.05; 1 year after CAS vs pretreatment or 1 week after CAS, P < 0.01.
-
